Background: Peripheral neuropathy is a frequent nosologic unit, its prevalence being estimated as 2-8% of the population. Polyneuropathy treatment is especially difficult in the axonal forms cases. To study the effectiveness of the medicines acting on the pathogenetic evolution of the polyneuropathy is very important. The objectives of the study have been to assess the efficiency of ipigrix (ipidacrin) with regard to the clinical state of the patients with idiopathic axonal polyneuropathy (IAP) and to determine its influence on electromyographic indices. Material and methods: 2 groups of 30 patients with IAP have been examined in an open controlled trial. In the complex treatment of the patients of group A ipigrix (ipidacrin) has been added – 15 mg (1.5% solution – 1.0 ml) intramuscularly for 20 days. The patients of group B have received a standard treatment. Results: After the course of the treatment in the both studied groups the improvement has been recorded both in clinic and electromyographic indices. But the statistically significant changes have been observed only in group A – in the patients who have additionally received ipidacrin. These changes have been related to the significant increase of the nerve conduction velocity in motor and sensory fibers of peripheral nerves. Conclusions: ipigrix (ipidacrin) positively influences and improves the clinical outcomes and electromyographic indices in the patients with IAP. It can be successfully used in the complex treatment of axonal polyneuropathies of other determined etiologies (diabetic, alcoholic, uremic, etc.).